Full Year 2022 Results

2022 Sales

$94.9B Worldwide Increased ▲ **1.3%**

Excluding acquisitions/ divestitures on an operational basis: Worldwide Increased ▲ **6.2%***

Diluted Earnings Per Share

$6.73 | Decreased ▼ **(13.8)%**

Adjusted Diluted Earnings Per Share*

$10.15 | Increased ▲ **3.6%**





Joaquin Duato
Chairman of the Board & Chief Executive Officer
Johnson & Johnson

"Our full year 2022 results reflect the continued strength and stability of our three business segments, despite macroeconomic challenges. I am inspired by our employees who make a difference in the health and lives of people around the world every day. As we look ahead to 2023, Johnson & Johnson is well-positioned to drive near-term growth, while also investing strategically to deliver long-term value."

$15.0 Billion

Worldwide Consumer Health Sales[2]

Consumer Health worldwide reported sales decreased (0.5)%, but increased 3.6% operationally[1]. Primary operational drivers:

Motrin IB · TYLENOL · Imodium · Neutrogena · SUDAFED · o.b.

$52.6 Billion

Worldwide Pharmaceutical Sales[2]

Pharmaceutical worldwide reported sales increased 1.7% or 6.7% operationally[1]. Primary operational drivers:

DARZALEX (daratumumab) injection for intravenous infusion 100 mg/5 mL, 400 mg/20 mL · Stelara (ustekinumab) · Erleada (apalutamide) 60 mg tablets · Tremfya (guselkumab) · INVEGA SUSTENNA paliperidone palmitate extended release injectable suspension · Uptravi selexipag tablets 200-1600 mcg

$27.4 Billion

Worldwide MedTech Sales

MedTech worldwide reported sales increased 1.4% or 6.2% operationally[1]. Primary operational drivers:

Electrophysiology · Contact Lens · Wound Closure · Surgical Vision · Trauma · Hips · Knees · Biosurgery · Endocutters · Energy

Note: values may have been rounded; the MedTech segment was previously referred to as the Medical Devices segment.

For full financial data and non-GAAP reconciliations, please refer to Johnson & Johnson's earnings release issued on January 24, 2023 available at http://www.investor.jnj.com/sales-earnings.cfm.

*Non-GAAP financial measure; non-GAAP financial measures should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures.

[1]Non-GAAP measure; excludes the impact of translational currency.

[2]Certain international OTC products, primarily in China, were reclassified from the Pharmaceutical segment to the Consumer Health segment based on operational changes.

Caution Concerning Forward-Looking Statements: This document contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding future operating and financial performance. You are cautioned not to rely on these forward-looking statements, which are based on current expectations of future events. For important information about the risks and uncertainties that could cause actual results to vary materially from the assumptions, expectations, and projections expressed in any forward-looking statements, review the "Note to Investors Concerning Forward-Looking Statements" included in the Johnson & Johnson earnings release issued on January 24, 2023 as well as the most recently filed Johnson & Johnson Reports on Forms 10-K and 10-Q. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.